Trust Company of Vermont’s Crescent Biopharma CBIO Stock Holding History

Trust Company of Vermont’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1	Closed	-$1K	–	887
2016 Q4	$1K	Hold	1	–	–	﹤0.01%	874
2016 Q3	$1K	Hold	1	–	–	﹤0.01%	809
2016 Q2	$1K	Hold	1	–	–	﹤0.01%	827
2016 Q1	$1K	Hold	1	–	–	﹤0.01%	720
2015 Q4	$1K	Hold	1	–	–	﹤0.01%	766
2015 Q3	$1K	Hold	1	–	–	﹤0.01%	774
2015 Q2	$1K	Hold	1	–	–	﹤0.01%	797
2015 Q1	$1K	Hold	1	–	–	﹤0.01%	759
2014 Q4	$1K	Hold	1	–	–	﹤0.01%	793
2014 Q3	$1K	Hold	1	–	–	﹤0.01%	790
2014 Q2	$1K	Hold	1	–	–	﹤0.01%	725
2014 Q1	$2K	Buy	+1	New	+$1.21K	﹤0.01%	712

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Trust Company of Vermont's CBIO Position: Q1 2017 in Review

Trust Company of Vermont sold out of Crescent Biopharma (CBIO) in Q1 2017, closing a stake of 1 share — an estimated $1K sold.

Trust Company of Vermont first reported a position in CBIO in Q1 2014 and held it in 12 quarters. The position peaked at $2K in Q1 2014. 43 funds tracked by Wall St. Rank hold CBIO as of Q1 2017.

Trust Company of Vermont reported no remaining Crescent Biopharma position as of Q1 2017 after selling out during the quarter.
Trust Company of Vermont sold 1 Crescent Biopharma share in Q1 2017, an estimated $1K.
Trust Company of Vermont first reported a position in Crescent Biopharma in Q1 2014 and held it in 12 quarters.
Trust Company of Vermont's Crescent Biopharma position peaked at $2K in Q1 2014.
43 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2017.

Based on Trust Company of Vermont's 13F filing for Q1 2017, filed 4 May 2017.